Oxford BioTherapeutics Announces First Patient Dosed in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
The start of this trial investigating its lead asset OBT076 in Adenoid Cystic Carcinoma (ACC) is a major milestone for OBT.
The start of this trial investigating its lead asset OBT076 in Adenoid Cystic Carcinoma (ACC) is a major milestone for OBT.
Boy Swallows Universe has become a hit since landing on Netflix.
C4X receives a milestone payment of $11 million from AstraZeneca.
Brouhaha’s latest production ‘Boys Swallows Universe’ releases new trailer.
Arecor’s ongoing progress from their licensed platform Arestat™ triggers milestone payment from Inhibrx Inc.
Calculus Capital’s investment director, Liz Klein, to discuss the dynamic world where capital meets compassion.
Richard Moore, Co-Head of Investments, gives his analysis on how a higher bank rate may affect the investment decisions made, and his outlook for the portfolio.
Oxford BioTherapeutics’s partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Wonderhood have been commissioned to produce a second season of Super Surgeons: A Chance at Life.
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.